SynthesisBMC nephrology2014
Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.
Synthesis in BMC nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.BMC nephrology · 2017Pooled it
- The road ahead: emerging therapies for primary IgA nephropathy.Frontiers in nephrology · 2025Review
- Development and Validation of a Machine Learning-Based Prognostic Model for IgA Nephropathy with Chronic Kidney Disease Stage 3 or 4.Kidney diseases (Basel, Switzerland) · 2024Article
- Contemporary review of IgA nephropathy.Frontiers in immunology · 2024Review
- Efficacy of prednisone combined with mycophenolate mofetil for immunoglobulin A nephropathy with moderate-to-severe renal dysfunction.World journal of clinical cases · 2023Article
- Prevalence of chronic kidney disease in a city of Northwestern China: a cross-sectional study.International urology and nephrology · 2023Article
- Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function.Clinical kidney journal · 2022Article
- Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy.Frontiers in medicine · 2022Article
- A Patient with MPO-ANCA-positive IgA Nephropathy Diagnosed with the Clinical Onset of Macrohematuria.Internal medicine (Tokyo, Japan) · 2019Article
- Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials.Experimental and therapeutic medicine · 2018Article
- IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology.Clinical kidney journal · 2018Article
- Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells.Pediatric nephrology (Berlin, Germany) · 2017Review
- Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.Oncotarget · 2017Article
- Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.Journal of endocrinological investigation · 2016Article
- Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.World journal of nephrology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgA nephropathy is the most common primary glomerular disease worldwide and also the most frequent cause of kidney failure. Mycophenolate mofetil (MMF) is a selective immunosuppressant widely used in many autoimmune diseases. However, the benefits and risks of MMF for the treatment of IgA nephropathy remain uncertain.
methodsA systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to assess the efficacy and safety of MMF in IgA nephropathy patients, using the statistical software Review Manager 5.1.
resultsEight RCTs involving 357 patients were identified and included in this review. Overall, no statistical difference was found in the therapeutic effect of MMF treatment compared with other therapies. MMF had no significant effects on reducing proteinuria or protecting renal function. However, subgroup analysis indicated that relatively short-term therapy (<18 months) might be beneficial in IgA nephropathy patients while longer term MMF use conferred no advantage. There was also no statistical difference between MMF and control groups in the incidence of side effects. When compared with other immunosuppressants, MMF was considered superior to cyclophosphamide in terms of better therapeutic effects and fewer adverse reactions, but no difference was found between MMF and leflunomide.
conclusionsOur current evidence indicates that a relatively short course of MMF may be beneficial in treating IgA nephropathy. However, high-quality RCTs with large sample size as well as a well-designed study to evaluate the long-term effects of MMF are needed to further evaluate the efficacy and safety of MMF in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.